Market LIVE
Published markets; coverage varies by country
Product profile · United States

TAGRISSO

 ·  Patent Litigation & Settlement History ↓

IngredientOSIMERTINIB MESYLATE
Application typeNDA
Application208065
Product002
Dosage formTABLET
RouteORAL
StrengthEQ 80MG BASE
Approval date2015-11-13
Marketing statusPrescription
Status event—
ApplicantASTRAZENECA
Product source

Current GenericRadar decision

Year2032
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2032-08-08
Patent anchor2032-08-08
Exclusivity anchor2020-11-13
Protection date—
First Final ANDA—
Status event—

QUALIFYING_ANCHOR_WITH_LATER_RIGHTS;

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
115249512032-07-25DS/DP ————
———
97320582032-07-25DS/DP/U U-3016———
———
97320582032-07-25DS/DP/U U-2289———
———
97320582032-07-25DS/DP/U U-1777———
———
97320582032-07-25DS/DP/U U-4010———
———
97320582032-07-25DS/DP/U U-3823———
———
89462352032-08-08DS/DP/U U-3016———
———
89462352032-08-08DS/DP/U U-3823———
———
89462352032-08-08DS/DP/U U-1777———
———
89462352032-08-08DS/DP/U U-4010———
———
89462352032-08-08DS/DP/U U-2289———
———
101830202035-01-02DP/U U-3016———
———
101830202035-01-02DP/U U-2289———
———
101830202035-01-02DP/U U-1777———
———
101830202035-01-02DP/U U-4010———
———
101830202035-01-02DP/U U-3823———
———
124656082042-11-26U U-3823———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
I-941—2027-02-16————Source
I-952—2027-09-25————Source
ODE-337—2027-12-18————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.